Jane Huang - 04 Feb 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: President, CMO
Issuer ticker: PRLD
Reported as of: 04 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2025, 16:31:16 UTC
Prior SEC filing: 07 Jan 2025
Next SEC filing: 07 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Krishna Vaddi, Attorney-in-Fact

Key filing fact

Jane Huang filed Form 4 for Prelude Therapeutics Inc (PRLD) on 05 Feb 2025.

Key facts

This page summarizes Jane Huang's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2025, 16:31.

Change

Previous filing in this sequence was filed on 07 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 04 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $1.11
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.